The president of Japanese drugmaker Takeda’s (TYO: 4502) consumer healthcare business, Masashi Sugimoto, is to step down after a year in the role.
Japanese press reports that Mr Sugimoto will resign at the end of the month, to be replaced provisionally by current chairman Yasuhiro Fukutomi.
Takeda announced in 2016 that it was spinning out its consumer healthcare division into a separate wholly-owned subsidiary, with the aim of expanding the business. The company started trading in April last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze